The initiative will apply its massive, multimodal dataset to build models that aim to improve diagnostic, prognostic, and predictive modeling
CHICAGO – Tempus AI, Inc. (NASDAQ: TEM), a company at the forefront of leveraging artificial intelligence to advance precision medicine, is launching its Fuses program. The initiative aims to unlock critical insights for patient care and research, using Tempus’ unparalleled data library and cutting-edge machine learning capabilities to develop an AI-powered diagnostic platform. The goal? To provide physicians with the most comprehensive suite of algorithmic tests designed to make precision medicine a reality.
Tempus has spent a decade building a multimodal data library that now boasts over 40 million research records. This treasure trove includes over 1.5 million records with linked clinical and genomic data, 2 million with imaging data, and approximately 300,000 with both genomic and whole transcriptomic data. This sheer volume of data unlocks the potential for groundbreaking discoveries previously unattainable.
The Fuses program will accelerate Tempus’ expansion of its AI-enabled diagnostic portfolio. The insights generated will be translated into clinically validated algorithmic tests, facilitating highly personalized care. This includes identifying patients unlikely to respond to existing therapies or those at risk of severe treatment-related complications. Tempus has already begun this journey, with the launch of its Immune Profile Score (IPS) last year, a multimodal biomarker used as a prognostic indicator for certain cancer patients undergoing immune checkpoint inhibitor therapy.
“Over the last ten years, we’ve built one of the industry’s most comprehensive datasets. We are now equipped to develop the world’s largest diagnostic model, poised to answer crucial, unsolved questions and transform our diagnostics into something smarter and more personalized,” stated Eric Lefkofsky, Founder and CEO of Tempus. “We are close to delivering genuine, transformative change, matching the right therapies to the right patients and turning personalized care into a reality for millions.”
The foundational model behind Fuses is focused on learning generalizable rules determining prognosis and drug benefit in real-world practice. This will enhance researchers’ capabilities to explore why certain clinical trials fail, uncover new uses for experimental drugs, optimize trial designs, and identify effective combination therapies to broaden patient benefit. By revealing the underlying biomarkers, the model may also highlight how drugs work and how resistance emerges, spurring a new generation of companion diagnostics and therapeutic research.
About Tempus
Tempus is revolutionizing precision medicine by applying artificial intelligence to healthcare. With one of the world’s largest multimodal data libraries and an operating system to make that data accessible, Tempus provides AI-enabled solutions to physicians, enabling personalized patient care. Concurrently, it fosters the discovery, development, and delivery of optimal therapeutics. The ultimate vision is to empower each patient to benefit from the experience of those who came before, equipping physicians with tools that continuously evolve as more data becomes available.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/1413.html
